News
GERN
3.690
-1.07%
-0.040
Weekly Report: what happened at GERN last week (0408-0412)?
Weekly Report · 5d ago
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
Shares of Argan, Inc. Rose sharply on Friday as the company reported better-than-expected results for its fourth quarter. The Dow Jones index fell over 250 points on Friday. Globe Life Inc. Shares rose 17% to $57.28 amid volatility. U.S. Stocks were lower in today's session.
Benzinga · 04/12 14:19
Considering The Merits Of A Gamble On Geron Corporation
FDA advisory committee voted 12-2 in favor of imetelstat's clinical profile in lower-risk myelodysplastic syndromes. The PDUFA target date for Geron Corporation's imetalstat NDA is June 16, 2024. GERN's IMproveMF trial in myelofibrosis isn't a near-term catalyst.
Seeking Alpha · 04/11 19:56
Jim Cramer: This Tech Stock Is "Great," Archer Aviation Is 'Too Speculative For Me'
Jim Cramer said MarineMax Inc is "just too risky" for him. The "Mad Money" host recommended selling Peabody Energy Corp and Archer Aviation Inc. He said he likes Trade Desk Inc and Uranium Energy Corp. Cramer was on CNBC's 'Mad Money Lightning Round'
Benzinga · 04/11 12:37
Geron Price Target Maintained With a $5.00/Share by Needham
Dow Jones · 04/11 10:29
Buy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development Progress
TipRanks · 04/11 10:05
Analysts Offer Insights on Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Geron (GERN) and Zur Rose Group AG (Six Swiss: CH:DOCM)
TipRanks · 04/11 09:07
The Latest Analyst Ratings For Geron
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. Geron has an average price target of $4.75 for the next 12 months. The company's drug in development, Imelstat, is being tested for the treatment of rare forms of cancer. In the last three months, 8 analysts have published ratings on Geron.
Benzinga · 04/10 19:01
Geron Price Target Maintained With a $6.00/Share by Wedbush
Dow Jones · 04/10 17:03
Wedbush Reiterates Outperform on Geron, Maintains $6 Price Target
Benzinga · 04/10 16:53
Geron To Present At Needham Virtual Healthcare Conference; Webcast At 10:15 AM ET
NASDAQ · 04/10 13:15
Weekly Report: what happened at GERN last week (0401-0405)?
Weekly Report · 04/08 09:00
Friday's ETF with Unusual Volume: PJP
NASDAQ · 04/05 16:13
Geron to Participate at Upcoming Investor Conferences in April
John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences. Geron is a late-stage clinical biopharmaceutical company. The company's first-in-class investigational telomerase inhibitor, imetelstat, is under review by the FDA.
Barchart · 04/03 15:30
Interesting GERN Put And Call Options For August 16th
NASDAQ · 04/02 14:41
Weekly Report: what happened at GERN last week (0325-0329)?
Weekly Report · 04/01 09:00
Weekly Report: what happened at GERN last week (0318-0322)?
Weekly Report · 03/25 09:00
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
NASDAQ · 03/21 14:01
Geron announces pricing of $150M underwritten offering
Healthcare Geron announces pricing of $150M underwritten offering. Geron Corporation expects proceeds of ~$150M from the offering. The company expects to use the proceeds to fund the potential commercialization of imetelstat in the U.S. And EU.
Seeking Alpha · 03/19 13:21
Geron Corporation Announces Pricing Of $150M Underwritten Offering Of Common Stock And Pre-Funded Warrants
Geron Corporation announces pricing of an underwritten offering of 41,999,998 shares of its common stock. The company is a late-stage clinical biopharmaceutical company. The offering is expected to raise $150.0 million. Geron intends to use the proceeds to fund the development of imetelstat.
Benzinga · 03/19 13:07
More
Webull provides a variety of real-time GERN stock news. You can receive the latest news about Geron Corp through multiple platforms. This information may help you make smarter investment decisions.
About GERN
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.